However, the gene therapy space faced significant regulatory challenges when the FDA requested Sarepta Therapeutics suspend distribution of Elevidys in July 2025 following reports of fatal acute liver failure in three patients. The safety concerns led to the suspension of shipments and implementation of enhanced safety monitoring protocols, highlighting the critical importance of ongoing safety surveillance in gene therapy development.